Pricing

SPDR Biotech ETF (XBI)

followers ยท
Information as of: 2024-06-30
Part of State Street Global Advisors - advised funds
LEI: 549300Y3ODFMPD5XXL58
Fund Type: Exchange-Traded Fund
617-664-8594
One Iron Street
Boston, US-MA 02210

www.ssga.com/spdrs

Advisers
Sub-Advisers
Taken from NPORT-P filing for 2024-12-31
Total Assets
$6.82b
Total Liabilities
$450m
Net Assets
$6.37b
Month 1 NAV Shares Sold
$1.66b
Month 1 NAV Shares Reinvested
$0.00
Month 1 NAV Shares Redeemed
$1.97b
Taken From Prospectus On: October 31, 2024
Expense Ratio: 0.35%
Fund Objective:
The investment objective of the SPDR S&P Biotech ETF is to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the biotechnology segment of a U.S. total market composite index.
Investment Strategy:
The fund employs a sampling strategy to track the performance of the S&P Biotechnology Select Industry Index. This means that the fund is not required to purchase all of the securities represented in the Index. Instead, the fund may purchase a subset of the securities in the Index in an effort to hold a portfolio of securities with generally the same risk and return characteristics of the Index.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
Please log in first to see chart
Period of ReportNameSymbolTitleTypeChangeAdditional InfoShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% ChangeLong/Short
No data available